Increasing the access to affordable medicine in developing countries and LDCs: between regulation and competition

Dr Sven Gallasch  
Centre for Competition Policy,  
United Kingdom

Dr Mor Bakhoum  
Max Planck Institute for Innovation and Competition, Germany
Background

Developed world
• Complex interplay of IP/Competition/pharma regulations
• Brand/generic dichotomy
• Prone to regulatory gaming – pharma antitrust

Developing world
• same dichotomy not necessarily applicable
• Less prevalent interplay – to a certain extent unknown
• How to increase access to affordable medicines through regulation and competition while avoiding regulatory gaming
Project – main research objectives

1. The status quo: identifying the relevant framework
2. Identifying barrier for entry to the pharmaceutical market
3. Providing advice on the improvement of access to affordable medicine
Project – the approach

1. **Data collection**
   Creation of panel data set through questionnaires, surveys and structured interviews

2. **Empirical research**
   Qualitative data analysis on a country by country basis and later on comparative basis

3. **Policy recommendations**
   min: comprehensive overview of access
   max: compare and delineate individual approaches
Project – categories of variables

• Pharmaceutical regulations
  • Incl. marketing authorisation, drug price regulation, substitution laws, parallel trade

• Competition legislation
  • Incl. US/EU model, policy goals, covering regulated markets, IP exemption, enforcement level, compulsory licensing

• IP legislation
  • Incl. TRIPS, patent enforcement system (bifurcation)
Project – categories of variables (cont)

- Procurement
- Sector specific information
  - Incl. supply side, demand side (buyer power, distribution, public/private health)
- Anticompetitive conduct
Questions and suggestions?

Please contact us:

Sven Gallasch  s.gallasch@uea.ac.uk

Mor Bakhoum  mor.bakhoum@ip.mpg.de